Literature DB >> 32268107

Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition.

Jason Gorman1, Gwo-Yu Chuang1, Yen-Ting Lai1, Chen-Hsiang Shen1, Jeffrey C Boyington1, Aliaksandr Druz1, Hui Geng1, Mark K Louder1, Krisha McKee1, Reda Rawi1, Raffaello Verardi1, Yongping Yang1, Baoshan Zhang1, Nicole A Doria-Rose1, Bob Lin1, Penny L Moore2, Lynn Morris2, Lawrence Shapiro3, John R Mascola1, Peter D Kwong4.   

Abstract

Antibodies targeting the V1V2 apex of the HIV-1 envelope (Env) trimer comprise one of the most commonly elicited categories of broadly neutralizing antibodies. Structures of these antibodies indicate diverse modes of Env recognition typified by antibodies of the PG9 class and the PGT145 class. The mode of recognition, however, has been unclear for the most potent of the V1V2 apex-targeting antibodies, CAP256-VRC26.25 (named for donor-lineage.clone and referred to hereafter as VRC26.25). Here, we determine the cryoelectron microscopy structure at 3.7 Å resolution of the antigen-binding fragment of VRC26.25 in complex with the Env trimer thought to have initiated the lineage. The 36-residue protruding loop of VRC26.25 displays recognition incorporating both strand-C interactions similar to the PG9 class and V1V2 apex insertion similar to the PGT145 class. Structural elements of separate antibody classes can thus intermingle to form a "combined" class, which in this case yields an antibody of extraordinary potency. Published by Elsevier Inc.

Entities:  

Keywords:  HIV-1 envelope trimer; PCT64; PG9; PGDM1400; PGT145; V1V2 apex recognition; broadly neutralizing antibody; multidonor antibody class; tyrosine sulfation

Mesh:

Substances:

Year:  2020        PMID: 32268107     DOI: 10.1016/j.celrep.2020.03.052

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  20 in total

1.  A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.

Authors:  Nitesh Mishra; Shaifali Sharma; Ayushman Dobhal; Sanjeev Kumar; Himanshi Chawla; Ravinder Singh; Bimal Kumar Das; Sushil Kumar Kabra; Rakesh Lodha; Kalpana Luthra
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

Review 2.  Targeting the N332-supersite of the HIV-1 envelope for vaccine design.

Authors:  Thandeka Moyo; Dale Kitchin; Penny L Moore
Journal:  Expert Opin Ther Targets       Date:  2020-04-27       Impact factor: 6.902

Review 3.  Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies.

Authors:  Nathaniel L Miller; Rahul Raman; Thomas Clark; Ram Sasisekharan
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

4.  Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.

Authors:  David Sacks; Kevin Wiehe; Lynn Morris; Penny L Moore
Journal:  J Virol       Date:  2022-05-05       Impact factor: 6.549

5.  Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.

Authors:  Gwo-Yu Chuang; Yen-Ting Lai; Jeffrey C Boyington; Cheng Cheng; Hui Geng; Sandeep Narpala; Reda Rawi; Stephen D Schmidt; Yaroslav Tsybovsky; Raffaello Verardi; Kai Xu; Yongping Yang; Baoshan Zhang; Michael Chambers; Anita Changela; Angela R Corrigan; Rui Kong; Adam S Olia; Li Ou; Edward K Sarfo; Shuishu Wang; Winston Wu; Nicole A Doria-Rose; Adrian B McDermott; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

6.  Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies.

Authors:  Emilie Seydoux; Yu-Hsin Wan; Junli Feng; Abigail Wall; Safia Aljedani; Leah J Homad; Anna J MacCamy; Connor Weidle; Matthew D Gray; Lauren Brumage; Justin J Taylor; Marie Pancera; Leonidas Stamatatos; Andrew T McGuire
Journal:  Cell Rep       Date:  2021-05-04       Impact factor: 9.423

7.  Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth.

Authors:  Ryan S Roark; Hui Li; Wilton B Williams; Hema Chug; Rosemarie D Mason; Jason Gorman; Shuyi Wang; Fang-Hua Lee; Juliette Rando; Mattia Bonsignori; Kwan-Ki Hwang; Kevin O Saunders; Kevin Wiehe; M Anthony Moody; Peter T Hraber; Kshitij Wagh; Elena E Giorgi; Ronnie M Russell; Frederic Bibollet-Ruche; Weimin Liu; Jesse Connell; Andrew G Smith; Julia DeVoto; Alexander I Murphy; Jessica Smith; Wenge Ding; Chengyan Zhao; Neha Chohan; Maho Okumura; Christina Rosario; Yu Ding; Emily Lindemuth; Anya M Bauer; Katharine J Bar; David Ambrozak; Cara W Chao; Gwo-Yu Chuang; Hui Geng; Bob C Lin; Mark K Louder; Richard Nguyen; Baoshan Zhang; Mark G Lewis; Donald D Raymond; Nicole A Doria-Rose; Chaim A Schramm; Daniel C Douek; Mario Roederer; Thomas B Kepler; Garnett Kelsoe; John R Mascola; Peter D Kwong; Bette T Korber; Stephen C Harrison; Barton F Haynes; Beatrice H Hahn; George M Shaw
Journal:  Science       Date:  2020-11-19       Impact factor: 47.728

8.  In vitro affinity maturation of broader and more-potent variants of the HIV-1-neutralizing antibody CAP256-VRC26.25.

Authors:  Yiming Yin; Brian D Quinlan; Tianling Ou; Yan Guo; Wenhui He; Michael Farzan
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-20       Impact factor: 11.205

Review 9.  HIV vaccinology: 2021 update.

Authors:  Jeong Hyun Lee; Shane Crotty
Journal:  Semin Immunol       Date:  2021-07-14       Impact factor: 10.671

Review 10.  Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies.

Authors:  Kshitij Wagh; Beatrice H Hahn; Bette Korber
Journal:  Curr Opin HIV AIDS       Date:  2020-09       Impact factor: 4.061

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.